Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVPET: PENG vs Combined Block for Secondary Hip Arthroplasty
NCT07109388Not yet recruiting
- Sponsor
- Lausanne University Hospital
- Start
- Sep 2025
- Primary completion
- Sep 2027
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
01
Overview
Randomised, double-blind trial of ropivacaine hydrochloride liposomal suspension injection in postoperative pain (2 arms), sponsored by Lausanne University Hospital. Primary endpoint: Cumulative postoperative morphine consumption at day 1. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
ropivacaine hydrochloride liposomal suspension injection
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT07109388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07109388.